Skip to main content
Erschienen in: medizinische genetik 3/2012

01.09.2012 | CME Zertifizierte Fortbildung

Hereditäre Fiebersyndrome

verfasst von: PD Dr. J. Schumacher, C. Timmann

Erschienen in: medizinische genetik | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das familiäre Mittelmeerfieber (FMF), Hyper-IgD-Syndrom (HIDS) und das Tumornekrosefaktor(TNF)-Rezeptor-1-assoziierte periodische Syndrom (TRAPS) sind monogene Krankheiten, die unter dem Begriff der hereditären Fiebersyndrome zusammengefasst werden. Sie sind durch rezidivierende Episoden mit Fieber und Entzündungszeichen gekennzeichnet und werden von Mutationen in Genen verursacht, denen eine Funktion bei der angeborenen Immunität zukommt. Die vorliegende Übersichtsarbeit befasst sich mit dem klinischen Erscheinungsbild und der Genetik der hereditären Fiebersyndrome. Sie sind für die humangenetische Beratung von Bedeutung.
Literatur
1.
Zurück zum Zitat Shohat M, Halpern G (2009) Familial Mediterranean Fever. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997–2011. Available at http://www.genetests.org Shohat M, Halpern G (2009) Familial Mediterranean Fever. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997–2011. Available at http://​www.​genetests.​org
2.
3.
Zurück zum Zitat Timmann C, Horstmann R (2009) Molecular diagnostics of hereditary fever syndromes. Familial Mediterranean fever (FMF), hyperimmunoglobulin D syndrome (HIDS), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), cryopyrin-associated periodic syndrome (CAPS: FCAS, MWS, NOMID/CINCA). Z Rheumatol 68:720–725PubMedCrossRef Timmann C, Horstmann R (2009) Molecular diagnostics of hereditary fever syndromes. Familial Mediterranean fever (FMF), hyperimmunoglobulin D syndrome (HIDS), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), cryopyrin-associated periodic syndrome (CAPS: FCAS, MWS, NOMID/CINCA). Z Rheumatol 68:720–725PubMedCrossRef
4.
Zurück zum Zitat Deltas CC, Mean R, Rossou E et al (2002) Familial Mediterranean fever (FMF) mutations occur frequently in the Greek-Cypriot population of Cyprus. Genet Test 6:15–21PubMedCrossRef Deltas CC, Mean R, Rossou E et al (2002) Familial Mediterranean fever (FMF) mutations occur frequently in the Greek-Cypriot population of Cyprus. Genet Test 6:15–21PubMedCrossRef
5.
Zurück zum Zitat Gross O, Thomas CJ, Guarda G, Tschopp J (2011) The inflammasome: an integrated view. Immunol Rev 243:136–151PubMedCrossRef Gross O, Thomas CJ, Guarda G, Tschopp J (2011) The inflammasome: an integrated view. Immunol Rev 243:136–151PubMedCrossRef
6.
Zurück zum Zitat Kallinich T, Haffner D, Niehues T et al (2007) Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics 119:474–483CrossRef Kallinich T, Haffner D, Niehues T et al (2007) Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics 119:474–483CrossRef
7.
Zurück zum Zitat Meinzer U, Quartier P, Alexandra JF et al (2011) Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum 41:265–271PubMedCrossRef Meinzer U, Quartier P, Alexandra JF et al (2011) Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum 41:265–271PubMedCrossRef
8.
Zurück zum Zitat Hilst JC van der, Bodar EJ, Barron KS et al (2008) Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine 87:301–310PubMedCrossRef Hilst JC van der, Bodar EJ, Barron KS et al (2008) Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine 87:301–310PubMedCrossRef
9.
Zurück zum Zitat Bader-Meunier B, Florkin B, Sibilia J et al (2011) Mevalonate kinase deficiency: a survey of 50 patients. Pediatrics 128:152–159CrossRef Bader-Meunier B, Florkin B, Sibilia J et al (2011) Mevalonate kinase deficiency: a survey of 50 patients. Pediatrics 128:152–159CrossRef
10.
Zurück zum Zitat Stoffels M, Simon A (2011) Hyper-IgD syndrome or mevalonate kinase deficiency. Curr Opin Rheumatol 23:419–423PubMedCrossRef Stoffels M, Simon A (2011) Hyper-IgD syndrome or mevalonate kinase deficiency. Curr Opin Rheumatol 23:419–423PubMedCrossRef
11.
Zurück zum Zitat Houten SM, Woerden CS van, Wijburg FA et al (2003) Carrier frequency of the V377I (1129G > A) MVK mutation, associated with Hyper-IgD and periodic fever syndrome, in the Netherlands. Eur J Hum Genet 11:196–200PubMedCrossRef Houten SM, Woerden CS van, Wijburg FA et al (2003) Carrier frequency of the V377I (1129G > A) MVK mutation, associated with Hyper-IgD and periodic fever syndrome, in the Netherlands. Eur J Hum Genet 11:196–200PubMedCrossRef
12.
Zurück zum Zitat Houten SM, Frenkel J, Rijkers GT et al (2002) Temperature dependence of mutant mevalonate kinase activity as a pathogenic factor in hyper-IgD and periodic fever syndrome. Hum Mol Genet 11:3115–3124PubMedCrossRef Houten SM, Frenkel J, Rijkers GT et al (2002) Temperature dependence of mutant mevalonate kinase activity as a pathogenic factor in hyper-IgD and periodic fever syndrome. Hum Mol Genet 11:3115–3124PubMedCrossRef
13.
Zurück zum Zitat Hull KM, Drewe E, Aksentijevich I et al (2002) The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine 81:349–368PubMedCrossRef Hull KM, Drewe E, Aksentijevich I et al (2002) The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine 81:349–368PubMedCrossRef
14.
Zurück zum Zitat Stojanov S, McDermott MF (2005) The tumour necrosis factor receptor-associated periodic syndrome: current concepts. Expert Rev Mol Med 7:1–18PubMedCrossRef Stojanov S, McDermott MF (2005) The tumour necrosis factor receptor-associated periodic syndrome: current concepts. Expert Rev Mol Med 7:1–18PubMedCrossRef
15.
Zurück zum Zitat Massonnet B, Normand S, Moschitz R et al (2009) Pharmacological inhibitors of the mevalonate pathway activate pro-IL-1 processing and IL-1 release by human monocytes. Eur Cytokine Netw 20:112–120PubMed Massonnet B, Normand S, Moschitz R et al (2009) Pharmacological inhibitors of the mevalonate pathway activate pro-IL-1 processing and IL-1 release by human monocytes. Eur Cytokine Netw 20:112–120PubMed
16.
Zurück zum Zitat Milhavet F, Cuisset L, Hoffman HM et al (2008) The infevers autoinflammatory mutation online registry: update with new genes and functions. Hum Mutat 29:803–808PubMedCrossRef Milhavet F, Cuisset L, Hoffman HM et al (2008) The infevers autoinflammatory mutation online registry: update with new genes and functions. Hum Mutat 29:803–808PubMedCrossRef
17.
Zurück zum Zitat Ravet N, Rouaghe S, Dode C et al (2006) Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene. Ann Rheum Dis 65:1158–1162PubMedCrossRef Ravet N, Rouaghe S, Dode C et al (2006) Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene. Ann Rheum Dis 65:1158–1162PubMedCrossRef
18.
Zurück zum Zitat Rebelo SL, Bainbridge SE, Amel-Kashipaz MR et al (2006) Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function. Arthritis Rheum 54:2674–2687PubMedCrossRef Rebelo SL, Bainbridge SE, Amel-Kashipaz MR et al (2006) Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function. Arthritis Rheum 54:2674–2687PubMedCrossRef
19.
Zurück zum Zitat Turner MD, Chaudhry A, Nedjai B (2012) Tumour necrosis factor receptor trafficking dysfunction opens the TRAPS door to pro-inflammatory cytokine secretion. Biosci Rep 32:105–112PubMedCrossRef Turner MD, Chaudhry A, Nedjai B (2012) Tumour necrosis factor receptor trafficking dysfunction opens the TRAPS door to pro-inflammatory cytokine secretion. Biosci Rep 32:105–112PubMedCrossRef
Metadaten
Titel
Hereditäre Fiebersyndrome
verfasst von
PD Dr. J. Schumacher
C. Timmann
Publikationsdatum
01.09.2012
Verlag
Springer-Verlag
Erschienen in
medizinische genetik / Ausgabe 3/2012
Print ISSN: 0936-5931
Elektronische ISSN: 1863-5490
DOI
https://doi.org/10.1007/s11825-012-0335-y

Weitere Artikel der Ausgabe 3/2012

medizinische genetik 3/2012 Zur Ausgabe

Personalia

Personalia

Schwerpunkt

Mito-Selbsthilfe

Einführung zum Thema

Mitochondriale Erkrankungen